. 2009 Apr 15;9:8. doi: 10.1186/1471-2210-9-8

Table 4.

Rapamycin plus sorafenib is more effective than single agent rapamycin in subcutaneous Tsc2^-/-tumors

	Untreated	Rapamycin	Sorafenib	Combination Rapamycin plus Sorafenib
Number of mice (n)	6	5	6	5

Median survival (days)	24.5	46	19.5	53
P value (survival)	-	0.0014*	NS*	0.0014* 0.0018^#

Day 16, average tumor volume (mm³)	1454 ± 215	284 ± 52	2209 ± 499	293 ± 68
P value (day 16)	-	0.0007*	NS*	0.0009*

Day 43, average tumor volume (mm³)	-	2499 ± 222	-	1665 ± 245
P value (day 43)	-	-	-	0.036^#

Day 44, average tumor volume (mm³)	-	2607 ± 247	-	1820 ± 245
P value (day 44)	-	-	-	0.06^#

Rapamycin (5 days per week)	-	8 mg/kg per day	-	8 mg/kg per day
Sorafenib (5 days per week)	-	-	60 mg/kg per day	60 mg/kg per day

*compared to untreated

^#compared to rapamycin treated

NS, not significant